Roche Holding AG (OTCPK:RHHVF)
$ 250.544 5.244 (2.14%) Market Cap: 204.93 Bil Enterprise Value: 223.02 Bil PE Ratio: 15.52 PB Ratio: 6.25 GF Score: 84/100

Roche Holding AG Efficacy and Safety of Risdiplam in Patients with Type 2/3 Spinal Muscular Atrophy Presented at SMA Europe 2020 Call Transcript

Feb 06, 2020 / 02:00PM GMT
Release Date Price: $346.1 (-0.33%)
Operator

Ladies and gentlemen, welcome to the Roche live audio webcast on efficacy and safety of the risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020. I'm Andre, the Chorus Call operator. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Karl Mahler, Head of Investor Relations. Please go ahead, sir.

Karl Mahler
Roche Holding AG - Head of IR

Yes. Thanks a lot. So good afternoon and good morning, ladies and gentlemen. A warm welcome from our side for everybody who is on the webcast and online here to review the SUNFISH data we just have presented at the SMA Europe in Paris. With us is Paulo Fontoura, he's the Global Head of Neuroscience and Rare Diseases Clinical Development, who will lead us through the data. And on the phone, we also have Michael Ostland, the Lifecycle Leader for the SMA program. You will have the opportunity to ask questions after the presentation and allow me also to thank Gerard Tobin and Sabine Borngraber from our team to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot